Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Annovis Bio, Inc. (ANVS : NYSE)

• Company Description    Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $1.98 Daily Weekly Monthly 20 Day Moving Average: 1,309,309 shares Shares Outstanding: 19.49 (millions) Market Capitalization: $38.58 (millions) Beta: 1.63 52 Week High: $10.54 52 Week Low: $1.11 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.65% -14.65% 12 Week -31.49% -34.32% Year To Date -60.64% -65.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101 Lindenwood Drive Suite 225 - Malvern,PA 19355 USA ph: 484-875-3192 fax: - ir@annovisbio.com http://www.annovisbio.com

• General Corporate Information    Officers Maria Maccecchini - Chief Executive Officer and President Michael Hoffman - Chairman of the Board and Director Claudine Bruck - Director Reid McCarthy - Director Mark White - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03615A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/14/25 Share - Related Items Shares Outstanding: 19.49 Most Recent Split Date: (:1) Beta: 1.63 Market Capitalization: $38.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.41 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.10 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 27.27% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -206.01 03/31/25 - -300.56 ROA 09/30/25 - - 06/30/25 - -158.26 03/31/25 - -193.50 Current Ratio 09/30/25 - - 06/30/25 - 7.65 03/31/25 - 10.68 Quick Ratio 09/30/25 - - 06/30/25 - 7.65 03/31/25 - 10.68 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 0.94 03/31/25 - 1.23 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©